Non-biologic immunosuppressive drugs for inflammatory and autoimmune skin diseases

被引:0
作者
Kanatoula, Danai Dionysia [1 ,2 ,3 ]
Bodner, Euna [1 ,2 ,3 ]
Ghoreschi, Kamran [1 ,2 ,3 ]
Meier, Katharina [1 ,2 ,3 ]
Solimani, Farzan [1 ,2 ,3 ,4 ,5 ]
机构
[1] Charite Univ Med Berlin, Dept Dermatol Venereol & Allergol, Berlin, Germany
[2] Free Univ Berlin, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
[4] Charite Univ Med Berlin, BIH Charite Clinician Scientist Program, Berlin Inst Hlth, BIH Biomed Innovat Acad, Berlin, Germany
[5] Charite Univ Med Berlin, Dept Dermatol Venereol & Allergol, Luisenstr 2, D-10117 Berlin, Germany
来源
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2024年
关键词
RHEUMATOID-ARTHRITIS PATIENTS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; LONG-TERM TREATMENT; CYCLOSPORINE-A; MYCOPHENOLATE-MOFETIL; CLINICAL PHARMACOKINETICS; METHOTREXATE TREATMENT; ANTIRHEUMATIC DRUGS; HYDROXYCHLOROQUINE; PREGNANCY;
D O I
10.1111/ddg.15270
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Non-biologic immunosuppressive drugs, such as azathioprine, dapsone or methotrexate are fundamental treatment options for a wide range of autoimmune and chronic inflammatory skin diseases. Some of these drugs were initially used for malignancies (e.g., azathioprine or methotrexate) or infectious diseases (e.g., hydroxychloroquine or dapsone) but are nowadays mostly used for their immunosuppressive/immunomodulating action. Although dermatologists have years of clinical experience with these drugs, some of the mechanisms of action are not fully understood and are the subject of research. Although these drugs are commonly used, lack of experience or knowledge regarding their safety profiles and management leads to skepticism among physicians. Here, we summarize the mechanism of action and detailed management of adverse effects of the most commonly used immunosuppressive drugs for skin diseases. Furthermore, we discuss the management of these drugs during pregnancy and breastfeeding, as well as their interaction and handling during vaccination.
引用
收藏
页码:400 / 421
页数:22
相关论文
共 120 条
[1]  
Alarcon GS, 1997, ARTHRITIS RHEUM, V40, P391, DOI 10.1002/art.1780400229
[2]   Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults [J].
Anderson, E. J. ;
Rouphael, N. G. ;
Widge, A. T. ;
Jackson, L. A. ;
Roberts, P. C. ;
Makhene, M. ;
Chappell, J. D. ;
Denison, M. R. ;
Stevens, L. J. ;
Pruijssers, A. J. ;
McDermott, A. B. ;
Flach, B. ;
Lin, B. C. ;
Doria-Rose, N. A. ;
O'Dell, S. ;
Schmidt, S. D. ;
Corbett, K. S. ;
Swanson, P. A., II ;
Padilla, M. ;
Neuzil, K. M. ;
Bennett, H. ;
Leav, B. ;
Makowski, M. ;
Albert, J. ;
Cross, K. ;
Edara, V. V. ;
Floyd, K. ;
Suthar, M. S. ;
Martinez, D. R. ;
Baric, R. ;
Buchanan, W. ;
Luke, C. J. ;
Phadke, V. K. ;
Rostad, C. A. ;
Ledgerwood, J. E. ;
Graham, B. S. ;
Beigel, J. H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (25) :2427-2438
[3]   INVITRO AND INVIVO EFFECTS OF DAPSONE ON NEUTROPHIL AND LYMPHOCYTE FUNCTIONS IN NORMAL INDIVIDUALS AND PATIENTS WITH LEPROMATOUS LEPROSY [J].
ANDERSON, R ;
GATNER, EMS ;
VANRENSBURG, CE ;
GRABOW, G ;
IMKAMP, FMGH ;
KOK, SK ;
VANRENSBURG, AJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1981, 19 (04) :495-503
[4]   EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome [J].
Andreoli, L. ;
Bertsias, G. K. ;
Agmon-Levin, N. ;
Brown, S. ;
Cervera, R. ;
Costedoat-Chalumeau, N. ;
Doria, A. ;
Fischer-Betz, R. ;
Forger, F. ;
Moraes-Fontes, M. F. ;
Khamashta, M. ;
King, J. ;
Lojacono, A. ;
Marchiori, F. ;
Meroni, P. L. ;
Mosca, M. ;
Motta, M. ;
Ostensen, M. ;
Pamfil, C. ;
Raio, L. ;
Schneider, M. ;
Svenungsson, E. ;
Tektonidou, M. ;
Yavuz, S. ;
Boumpas, D. ;
Tincani, A. .
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (03) :476-485
[6]   Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome [J].
Belizna, Cristina .
AUTOIMMUNITY REVIEWS, 2015, 14 (04) :358-362
[7]   Development of dapsone toxicity in patients with inflammatory dermatoses: Activity of acetylation and hydroxylation of dapsone as risk factors [J].
Bluhm, RE ;
Adedoyin, A ;
McCarver, DG ;
Branch, RA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (06) :598-605
[8]  
Boffa MJ, 1996, BRIT J DERMATOL, V135, P538, DOI 10.1046/j.1365-2133.1996.d01-1036.x
[9]   Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology [J].
Broen, Jasper C. A. ;
van Laar, Jacob M. .
NATURE REVIEWS RHEUMATOLOGY, 2020, 16 (03) :167-178
[10]   Clinical pharmacokinetics of mycophenolate mofetil [J].
Bullingham, RES ;
Nicholls, AJ ;
Kanmm, BR .
CLINICAL PHARMACOKINETICS, 1998, 34 (06) :429-455